In the battle of the big biotech stocks, how do Gilead and Amgen stack up against each other?
Two of the biggest biotechs have produced quite different results for shareholders. Amgen's (NASDAQ:AMGN) valuation nearly doubled during the the last five years, while Gilead Sciences' (NASDAQ:GILD) stock price more than quadrupled.
Looking only at performance this year is a different story altogether. Amgen has basically tread water, with shares close to the same price as at the beginning of 2016. Gilead's stock price, on the other hand, has dropped by a double-digit percentage year-to-date.
All of that is in the past, though. Which of these big biotech stocks is the better pick for long-term investors going forward? Let's see how Gilead and Amgen stack up against each other.
Continue to read at The Motley Fool …